Comprehensive Online Oncology Database
New Medicine Oncology KnowledgeBASE
 NEWS
SUBSCRIBER SEARCH
(Requires Login)
NEW DRUG
MARKETED DRUG
COMPANY
TARGETS IN ONCOLOGY
NEWS AND WEBCAST SUMMARIES
COMBINATION TRIALS
  
   1-949-830-0448   info@newmedinc.com   
 
ABOUT nm|OK
nm|OK FREE ACCESS AND DEMO
APPLICATIONS
DESCRIPTION OF MODULES
INQUIRIES AND FEEDBACK
LICENSE AGREEMENT
PRIVACY POLICY
SAMPLE QUERY SCREENS
SAMPLE REPORTS & RECORDS
SOURCES
SUBSCRIPTION INFORMATION
USER GUIDE

PRODUCTS AND SERVICES
FUTURE ONCOLOGY
FEATURED IN-DEPTH REPORTS
CUSTOM REPORT REQUEST

NEWS
NEWS SUMMARIES
LATEST nm|OK UPDATES
nm|OK NEWS RELEASES

SITE MAP
Having trouble finding something?
Use our site map.
  

Latest Updates
June 2008 Combination Trial Updates and Additions

Protocol ID
 Trial Title
CDR0000469850; NU-05B5; NU-1838-001; NCT00316875 A Phase I, Open-Label Trial of the Safety, Tolerability and Pharmacokinetics of Lapatinib in Combination With Liposomal Doxorubicin in Patients With Metastatic Breast Cancer

HOME   |   NEW MEDICINE   |   SITE MAP

NEW MEDICINE, INC.
P.O. BOX 909, LAKE FOREST, CA 92609
PHONE:  1-949-830-0448     FAX:  1-949-830-0887
INFO@NEWMEDINC.COM